| |
 |
 |
 |
 |
 |
 |
 |
August 4, 2003
AnGes MG
and Gene Design Inc. establish joint operations
-
Granting manufacturing and marketing rights for a novel nucleic
acid sequence - |
 |
|
|
Today AnGes MG, Inc. concluded a licensing agreement
with Gene Design Inc., a company specializing in the synthesis
of agents on the basis of nucleic acid. The agreement provides
for AnGes MG to license the manufacture of nucleic acid according
to its novel technique (patent pending) for subsequent use as
a reagent in Gene Design's research.
AnGes MG has been developing NF B
decoy oligo nucleotides. Decoy and antisense agents on the basis
of nucleic acid have been developed in Japan and abroad to treat
cancer and other chronic inflammations.
The novel nucleic acid to be manufactured and distributed by
Gene Design Inc. comprises a type of new decoy nucleotides.
Upon AnGes MG's granting of rights for manufacturing and marketing
of the nucleic acid for research purposes to Gene Design, Inc.,
which specializes in nucleic acid synthesis, the nucleotides
will become accessible to a wide variety of research institutions
in Japan and abroad. Better opportunities for research on reactions
to therapeutic agents will enable the nucleotides to be used
as therapeutic agents in future.
AnGes MG has submitted a patent application for the novel nucleic
acid sequence, the royalties from Gene Design Inc. will contribute
to the Company's revenue.
The effect of the cooperative agreement on the Company's earnings
cannot be determined at present. |
| Reference |
|
|
|
 Explanation
of specialized terms
1.
Nucleotide
A fraction of a genetic expression, since it is extracted
from nucleic acid (DNA or RNA), it is referred to as nucleotide.
Nucleotides can be artificially synthesized.
2. Decoy nucleotides
A genetic expression features a switch - genetic factor - bonded
to a genome. A decoy is a "compressed" nucleic acid
of the same array as the aforementioned genetic factors, which
when introduced to the body, neutralizes those "switches"
by preventing their bonding to a genome, thereby regulating
the transcription process.
3.
Antisense nucleotides
The information in DNA has to be transcribed to mRNA for protein
synthesis to begin, and thus - for a genetic expression to "work".
The antisense nucleotides supplement mRNA; when introduced to
the body, these nucleotides bond to mRNA, thereby regulating
the transcription process.
4. NF B
(nuclear factor-kappa B)
NFB
is a genetic factor enabling regulation of cytocines and adhesion
factors - related to immunological reactions. Bonding NFB
to a genome causes excessive transcription of immunization-related
genetic expressions. This is why NFB
has been indicated as one of the causes of atopic dermatitis,
rheumatic arthritis, miocardium infarctions, arteriosclerosis.
In addition, regular medicine, such as steroids, or aspirin,
even antioxidants are used to inhibit NFB.
5. NFB
decoy oligo-deoxy-nucleotide
A decoy nucleotide against NFB.
AnGes MG is developing therapeutic agents on the basis of its
properties to treat patients suffering from atopic dermatitis,
rheumatic arthritis, and restenosis - conditions caused by excessive
immunological response. |
| Company
Profile |
|
|
|
| Corporate name: |
Gene Design Inc. |
| Headquarters: |
3-6-301, Mihogaoka, Ibaragi, Osaka, Japan |
| Head of the company: |
Hirotoshi Yuyama |
| Established: |
December, 2000 |
| Paid-in capital: |
¥ 10,000,000 (As of June 2003) |
| Number of employees: |
13 |
| Revenue: |
¥ 72,000,000 (As of October 2002) |
| Operations: |
Contracting of DNA synthesis, development of innovative
nucleic acid synthesis technology, etc. |
|
|
|
